The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Myriad receives reimbursement for the BRACAnalysis Diagnostic System in Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Myriad Genetics has received reimbursement and launched the BRACAnalysis Diagnostic System in Japan to help physicians determine which people affected with breast and ovarian cancer have hereditary breast and ovarian cancer syndrome and qualify for additional diagnostic and medical management.

BRACAnalysis was approved by Japan’s Ministry of Health, Labour and Welfare in November 2019 for this indication.

Table of Contents

YOU MAY BE INTERESTED IN

NCI Director's Report

As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”

NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.
By Jacquelyn Cobb
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account